Across 6 scored articles from Oct 16 to Nov 14, 2026 (UTC),
the average sentiment of Edwards Lifesciences news is Bullish (+64)
on a scale from −100 to +100.
That is up 15 points from the previous 30 days (+49).
📉 VP Donald Bobo, Jr. sold 48,900 shares for $5.04 million under a pre-arranged Rule 10b5-1 trading plan on November 9th.
💰 The company reported Q3 EPS of $0.80, beating the consensus estimate of $0.74 by $0.06.
📈 Revenue reached $1.72 billion, surpassing the $1.68 billion consensus and growing 10.5% year-over-year.
🏦 Institutional ownership stands at 79.46%, with Intech Investment Management increasing its stake by 123.9% in Q3.
🎯 Analysts maintain a 'Moderate Buy' consensus with an average price target of $108.88, up from recent lows.
📊 The stock trades at a P/E ratio of 59.16 and has a market capitalization of $60.29 billion.
📈 Bullish signals
💰Edwards Lifesciences beat Q3 earnings estimates with $0.80 EPS versus the consensus of $0.74.
📈Revenue grew 10.5% year-over-year to $1.72 billion, exceeding analyst expectations of $1.68 billion.
🎯Goldman Sachs raised its price target to $102.00 and reaffirmed a 'buy' rating on the stock.
🏦Intech Investment Management increased its stake by 123.9% in Q3, now holding shares valued at $16.6 million.
🎯Truist Financial set a price objective of $113.00 with a 'buy' rating following the earnings beat.
🎯Piper Sandler raised its price target to $115.00 and maintained an 'overweight' rating on the company.
📉 Risk factors
📉VP Donald Bobo, Jr. reduced his personal shareholding by 68.2% following a $5.04 million sale.
📊The stock trades at a high P/E ratio of 59.16, which may limit upside potential if growth slows.
Article
Edwards Lifesciences Corporation (NYSE:EW) saw Vice President Donald Bobo, Jr. sell 48,900 shares on November 9th under a pre-arranged Rule 10b5-1 trading plan. The transaction averaged $103.05 per share, totaling approximately $5.04 million, reducing his personal holding to roughly 22,798 shares. This insider sale represents a significant decrease in his position but was executed via a standard compliance plan.
The company reported strong quarterly financial results on November 4th, beating analyst expectations for both earnings per share and revenue. Edwards Lifesciences posted $0.80 EPS compared to the consensus of $0.74, while revenue reached $1.72 billion against an estimate of $1.68 billion. Year-over-year revenue growth stood at 10.5%, driven by its structural heart disease therapies and critical care technologies.
Market sentiment remains robust with a consensus price target of $108.88, supported by recent upgrades from major analysts including Goldman Sachs, Jefferies, and Truist Financial. Institutional ownership is high at 79.46%, with several funds like Intech Investment Management increasing their stakes in the third quarter. The stock trades at a P/E ratio of 59.16 with a market capitalization of $60.29 billion.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
Barclays raised its price target on Edwards Lifesciences Corporation (NYSE: EW) to $110 from $104 in a research note published on April 27, reaffirming its "Overweight" rating for the medical device stock. This positive adjustment followed the company's fiscal first-quarter earnings release on April 23, which highlighted share gains across Europe and the United States. In the quarter, Edwards reported a significant increase in overall sales, with fiscal Q1 revenue rising 16.7% to $1.65 billion, while constant currency sales grew by 12.7%.
The financial performance was particularly strong within the Transcatheter Aortic Valve Replacement (TAVR) segment, where sales increased 14.4% to reach $1.20 billion, with constant currency growth of 11.0%. Edwards also noted that fiscal Q1 sales for Transcatheter Mitral and Tricuspid Therapies (TMTT) reached $173 million, driven by repair and replacement therapies. Capitalizing on these positive operational results and market performance, the company upgraded its guidance for fiscal year 26, projecting constant currency sales growth between 9% and 11%, up from the previous range of 8% to 10%. Additionally, Edwards raised the midpoint of its adjusted EPS guidance for FY26 to a new range of $2.95 to $3.05, extending the prior range of $2.90 to $3.05.
Edwards Lifesciences continues to focus on patient-centered medical innovations for heart disease and critical care monitoring, with product lines categorized into Transcatheter Aortic Valve Replacement, TMTT, Surgical Structural Heart, and Critical Care segments. The company operates across four geographical regions: the United States, Europe, Japan, and Rest of the World. While the article notes Barclays' bullish stance and highlights Jim Cramer's observation that Edwards is in a "good zone," it also includes a disclaimer stating that Yahoo Finance is not a broker-dealer or investment adviser, alongside a separate promotional segment suggesting alternative AI stocks for specific market trends.
📈 Barclays raised the price target to $110 with an Overweight rating.
💰 Fiscal Q1 sales rose 16.7% to $1.65 billion driven by global gains.
❤️ TAVR revenue surged 14.4%, leading Edwards to raise FY26 growth guidance.
🏥 Company maintains focus on structural heart innovations while raising EPS outlook.
🤖 Analysts suggest AI stocks may offer higher upside potential than the ticker.
📈 Barclays raised its price target on Edwards Lifesciences (EW) to $110 from $104, maintaining an Overweight rating after Q1 earnings.
💰 Fiscal Q1 sales increased 16.7% year-over-year to $1.65 billion on a GAAP basis.
🌍 Sales in Europe and the United States specifically showed gains in the most recent quarter.
❤️ TAVR (Transcatheter Aortic Valve Replacement) sales jumped 14.4% to $1.20 billion, with constant currency growth of 11%.
🔧 TMTT (Transcatheter Mitral and Tricuspid Therapies) sales reached $173 million, driven by repair and replacement procedures.
📈 Edwards Lifesciences raised its fiscal 2026 constant currency sales growth guidance to between 9% and 11%, up from 8-10%.
💹 The company also increased its adjusted EPS guidance midpoint range for FY26 to $2.95-$3.05 from a previous $2.90-$3.05.
🏗️ Operations are segmented by geography into the United States, Europe, Japan, and Rest of World.
💡 Business units focus on Transcatheter Aortic Valve Replacement, Mitral/Tricuspid Therapies, Surgical Structural Heart, and Critical Care.
📢 Jim Cramer noted that Edwards Lifesciences is currently in a "Good Zone" regarding its market position.
🏥 The company specializes in patient-focused medical innovations for heart disease and critical care monitoring.
🤖 Analysts at Insider Monkey believe certain AI stocks offer greater upside potential than EW despite positive earnings.
Bullish Signals
Barclays raised the price target for Edwards Lifesciences Corporation (NYSE:EW) to $110 from $104, reaffirming an Overweight rating following strong Q1 earnings.
Fiscal Q1 sales rose 16.7% year-over-year to $1.65 billion, while constant currency sales grew 12.7%, demonstrating robust revenue expansion.
TAVR sales specifically surged 14.4% to $1.20 billion with constant currency growth of 11.0%, highlighting demand in its core structural heart business.
The company successfully raised its FY26 constant currency sales growth guidance to a range of 9% to 11%, upgrading from the previous expectation of 8% to 10%.
Edwards Lifesciences also increased its FY26 adjusted EPS guidance midpoint, expanding the forecasted range to $2.95 to $3.05 from the prior $2.90 to $3.05.
Share gains were reported in both Europe and the United States during the quarter, indicating positive international performance alongside domestic strength.
Risk Factors
Despite the upgrade, the article explicitly argues that 'certain AI stocks offer greater upside potential and carry less downside risk' compared to Edwards Lifesciences.
The piece suggests Edwards Lifesciences is not as attractive in the current environment, directing readers toward an 'undervalued AI stock' for better short-term returns under Trump-era tariffs.
Edwards Lifesciences (EW) is experiencing a divergence among investment analysts regarding its growth trajectory and risk profile, leading to widely varying price targets and fair value assessments. While several firms including Barclays, Truist, Evercore ISI, BTIG, Baird, and Piper Sandler have raised their price targets by $1 to $6, signaling confidence in Edwards' execution capabilities, other major institutions like Goldman Sachs, UBS, and BofA have reduced theirs, with Goldman cutting its target by $13. This split reflects ongoing debate over the balance between growth expectations from new product launches and potential headwinds such as competition in left atrial appendage closure and the scalability of new technologies. Specifically, Wolfe Research upgraded the stock citing value creation potential in core surgical franchises, whereas cautious calls highlight risks related to valuation relative to execution and competitive pressures noted by Oppenheimer regarding AtriCure.
Company fundamentals have been clarified through recent guidance and clinical data released in April 2026. Edwards provided sales guidance projecting full-year revenue between $6.5 billion and $6.9 billion, representing growth of 8% to 10%, with Q2 expected to range from $1.66 billion to $1.74 billion. Earnings per share is forecasted between $2.90 and $3.05 for the full year. Clinically, new data on the EVOQUE transcatheter tricuspid valve replacement system presented at ACC.26 demonstrated two-year results showing near elimination of regurgitation, improved quality of life, and lower mortality rates supported by registry data from over 1,000 patients. Additionally, Edwards reported significant share repurchase activity in Q4 2025, buying back approximately 524,543 shares for $39.8 million, bringing total buybacks under the program to roughly $3.5 billion representing 7.86% of outstanding shares.
Simply Wall St's valuation model adjusted its fair value estimate marginally from $96.93 to $96.96 based on shifts in underlying assumptions reflecting the current market narrative. The model assumes a slightly lower revenue growth rate of 9.56% compared to 9.94% previously, but a higher net profit margin of 25.75% versus 25.09%, alongside a reduced future P/E multiple expectation falling from 33.81x to 31.73x and a minimal increase in the discount rate from 7.81% to 7.84%. The analysis connects these financial metrics to key product narratives involving TAVR, EVOQUE, and Sapien M3 systems intended to expand structural heart therapy revenue, while acknowledging significant risks including tariffs, the JenaValve acquisition, competitive pressure in Japan, and potential margin erosion from higher R&D spend if growth targets are missed.
📈 Fair value edge shifted minimally from US$96.93 to US$96.96 despite mixed analyst sentiment.
⚖ Bullish investors favor product launches while bears worry about competitive pressure and scaling risks.
💰 2026 guidance projects sales of US$6.5b-$6.9b with EPS between US$2.90-$3.05 per share.
📈 Edwards Lifesciences' modeled fair value edge has shifted minimally from US$96.93 to US$96.96 despite diverging analyst sentiment.
📉 Analyst price targets are split, with bullish firms like Barclays and Truist raising targets by $1-$6 due to pipeline execution confidence.
🐻 Bearish analysts including Goldman Sachs and UBS reduced targets significantly, citing valuation concerns relative to execution risk.
⚖️ Bull arguments focus on Edwards' ability to deliver new product launches and maintain core surgical franchises.
🛑 Bear concerns highlight competitive pressure in areas like atrial appendage closure and risks that new products may take time to scale.
💰 Company guidance for 2026 projects full-year sales between US$6.5b and US$6.9b with an EPS range of US$2.90-$3.05.
🔬 Recent TRISCEND II data for the EVOQUE tricuspid valve system showed improved quality of life and lower all-cause mortality in registry data.
💸 The company completed a share repurchase program, buying back over 47 million shares for approximately US$3.5 billion through the end of 2025.
📊 Fair value model assumptions were adjusted slightly, with revenue growth expectations dropping from 9.94% to 9.56%.
📉 Net profit margin assumptions increased in the model from 25.09% to 25.75%, potentially offsetting some valuation pressure.
🤖 Analysts' P/E assumptions were revised down from 33.81x to 31.73x, reflecting a more conservative long-term multiple outlook.
⚠️ Key investment risks identified include tariffs, the JenaValve acquisition, competitive pressures in markets like Japan, and high R&D spend.
🔬 Future narratives will track how TAVR, EVOQUE, and Sapien M3 products expand treatment options across structural heart therapies.
🌍 Global therapy adoption trends, RESILIA tissue technology, and guideline changes remain central to margin and usage assumptions.
Bullish Signals
Major analysts lifted Edwards Lifesciences price targets by $1 to $6.
Edwards projects 2026 sales growth of 8% to 10% between $6.5b-$6.9b.
TRISCEND II data showed near TR elimination and lower mortality in 1,000+ patients.
Company bought back 524,543 shares for $39.8m in late 2025.
Net profit margins improve from 25.09% to 25.75% as product lines scale.
Risk Factors
Analyst downgrades signal high valuation risks and execution uncertainty.
Competition fears target left atrial appendage closure market share.
Tariffs and acquisition integration pose major operational hurdles.
Japanese market pressure threatens international revenue expansion.
Increased R&D spending may erode current profit margins.
Bullish Signals
Barclays, Truist, Evercore ISI, BTIG, Baird, and Piper Sandler have lifted their price targets by US$1 to US$6, signaling strong analyst confidence in Edwards Lifesciences at current valuation levels.
Edwards issued robust 2026 guidance, projecting full-year sales between US$6.5b and US$6.9b with a growth rate of 8% to 10%, reflecting optimistic management expectations.
New TRISCEND II data for the EVOQUE transcatheter tricuspid valve replacement system showed near elimination of tricuspid regurgitation, lower all-cause mortality, and no added device-related risk, supported by registry data from more than 1,000 patients.
The company continues to return capital to shareholders through an aggressive share repurchase program, having spent US$39.8m between October 1, 2025 and December 31, 2025 to buy back 524,543 shares.
Analyst models reflect improving profitability assumptions with net profit margins shifting up from 25.09% to 25.75%, indicating potential for margin expansion as the company scales its product lines.
Risk Factors
Analyst downgrades from Goldman Sachs (-US$13) and Canaccord, alongside concerns over high valuation relative to execution risk, suggest significant uncertainty around growth assumptions.
Goldman Sachs' price target reduction highlights specific fears regarding competition in the left atrial appendage closure market, particularly against rivals like AtriCure.
Key risks identified include tariffs, potential integration issues from the JenaValve acquisition, competitive pressures specifically in the Japanese market, and increased R&D spending that could erode profit margins.
The divergence in analyst opinions, with some trimming targets by as much as US$13 due to execution risk, indicates a lack of consensus on the company's future ability to scale new products.
Analysts are concerned that new product launches may take too long to scale effectively, potentially impacting near-term revenue growth despite positive pipeline data.
The model assumes a reduction in revenue growth from 9.94% to 9.56%, reflecting cautious expectations about the company's ability to maintain its historical growth trajectory.
Edwards Lifesciences Corporation (EW) reported first-quarter 2026 adjusted earnings per share (EPS) of 78 cents, surpassing the Zacks Consensus Estimate by 16.4% and representing a 21.9% year-over-year increase. While sales totaled $1.65 billion, matching the consensus estimate, they grew 17% year over year. One-time adjustments primarily included litigation and restructuring expenses, with GAAP EPS from continuing operations at 66 cents compared to 62 cents in the prior period. Following the announcement, EW stock climbed 2.3% in aftermarket trading. The company attributed growth in its Transcatheter Aortic Valve Replacement (TAVR) group, which reached $1.20 billion globally, to heightened clinician focus on SAPIEN therapy and proactive disease management for severe aortic stenosis patients. Similarly, Transcatheter Mitral and Tricuspid Therapies (TMTT) sales rose 51.9% to $175.1 million due to the adoption of PASCAL and EVOQUE products.
Financially, gross profit reached $1.29 billion, up 15.7%, though the gross margin contracted 64 basis points to 78% driven by a 20.2% increase in the cost of sales. SG&A expenses increased 12.1% to $522.2 million, while R&D expenditures rose modestly by 3.4% to $263.3 million. Despite these expenses, operating income jumped 28.1% year over year to $500.5 million, with the operating margin expanding significantly by 269 basis points to 30.4%. The company's cash and cash equivalents stood at $2.40 billion as of the end of the quarter, a decrease from $3.00 billion in the fourth quarter of 2025, while total debt remained roughly $600 million, consistent with the prior year.
Looking ahead, Edwards raised its full-year 2026 outlook, projecting sales growth between 9% and 11%, which exceeds the Zacks Consensus Estimate pegged at 9.8%. Adjusted EPS for 2026 is now guided in the $2.95-$3.05 range, above the consensus of $2.96. For the second quarter of 2026, the company expects sales between $1.66 billion and $1.74 billion with adjusted EPS in the 70-76 cents range. Management highlighted continued growth drivers including the extended durability of RESILIA therapies in surgical operations, which includes INSPIRIS, KONECT, and MITRIS platforms. The article notes that while gross margin contraction is a concern, the expansion in operating margins remains a positive indicator, though EW currently holds a Zacks Rank #3 (Hold).
📈 Q1 EPS hit $0.78, beating estimates by 16.4% with revenue up 17%.
💰 Operating income surged 28.1% to $500.5M despite a minor margin squeeze.
🚀 Full-year 2026 guidance raised as TAVR and surgical therapies expand globally.
⚖️ Analysts rate Edwards a Hold, though sector peers show strong buy signals.
Edwards Lifesciences reported first-quarter 2026 adjusted EPS of $0.78, beating analyst estimates by 16.4% and rising 21.9% year-over-year.
Total Q1 revenue was $1.65 billion, matching the Zacks Consensus Estimate and increasing 17% compared to the prior year.
Stock price climbed 2.3% in aftermarket trading following the earnings announcement of strong financial performance.
TAVR segment sales reached $1.20 billion, reflecting increased clinician adoption of SAPIEN therapy and proactive management of severe aortic stenosis patients.
TMTT unit revenue grew 51.9% year-over-year to $175.1 million, driven by global adoption of PASCAL and EVOQUE product lines.
Surgical sales rose 10.1% year-over-year, primarily due to continued expansion of RESILIA therapies that offer extended durability.
Gross profit increased 15.7% to $1.29 billion, though the gross margin contracted by 64 basis points to 78% due to higher cost of sales.
Operating income expanded significantly by 28.1% year-over-year to $500.5 million, resulting in an operating margin expansion of 269 basis points.
The company ended Q1 with $2.40 billion in cash and cash equivalents, while total debt remained stable at roughly $600 million.
Management raised its full-year 2026 sales growth guidance to between 9% and 11%, citing strong catalysts and differentiated therapies.
For the second quarter of 2026, Edwards projects sales between $1.66 billion and $1.74 billion with adjusted EPS between 70 and 76 cents.
Analysts noted that while gross margin contraction is a concern, the expansion in operating margins signals positive operational efficiency.
Zacks Investment Research assigns Edwards Lifesciences a Rank #3 (Hold) based on its current market valuation and earnings trajectory.
The broader medical device sector saw other notable performers like Globus Medical with a Rank #1 (Strong Buy) rating following their own Q4 beat.
Globus Medical reported fourth-quarter 2025 adjusted EPS of $1.28 and revenue of $826.4 million, both surpassing analyst expectations.
Tactile Systems Technology achieved a Rank #2 (Buy) status with Q4 EPS of $0.46 and revenues of $103.6 million beating estimates.
Phibro Animal Health displayed strong consistency with positive earnings surprise in each of its last four quarters of fiscal 2026.
These recommendations suggest diversification opportunities for investors looking beyond Edwards Lifesciences within the healthcare technology space.
Bullish Signals
Edwards Lifesciences beat Q1 earnings estimates with adjusted EPS of 78 cents, exceeding the consensus by 16.4% and marking a 21.9% year-over-year increase.
Sales reached $1.65 billion, aligning perfectly with analyst expectations while growing 17% year over year to demonstrate strong demand.
The TAVR segment drove significant growth with global sales up 14.4% to $1.20 billion, fueled by increased adoption of the SAPIEN 3 Ultra RESILIA platform.
Transcatheter Mitral and Tricuspid Therapies saw explosive growth, with sales surging 51.9% year over year as clinicians adopt PASCAL and EVOQUE devices.
Global Surgical sales grew 10.1% to $276.2 million, driven by the sustained market uptake of RESILIA therapies which offer extended durability.
Operating income expanded 28.1% year over year to $500.5 million, reflecting an operating margin expansion of 269 basis points to 30.4%.
Management raised its full-year 2026 sales growth guidance range from 8-10% to 9-11%, signaling confidence in continued market momentum.
The company strengthened its balance sheet with $2.40 billion in cash and cash equivalents while maintaining manageable debt levels around $600 million.
Risk Factors
Gross profit margins contracted by 64 basis points year over year to 78%, primarily due to a significant 20.2% increase in the cost of sales.
Cash and cash equivalents decreased from $3.00 billion in the fourth quarter of 2025 to $2.40 billion at the end of Q1 2026, indicating a drawdown in liquidity despite strong revenue growth.
The company's Q2 guidance for adjusted EPS is lower than Q1 results ($0.70-$0.76 vs the implied prior quarter strength), suggesting a potential peak in profitability this year.
Edwards Lifesciences Corp. reported first-quarter results that exceeded analyst expectations, driving its shares up 4.7% to $83.49 in after-hours trading with a market capitalization of approximately $46 billion. The Irvine-based medical device company posted revenue of $1.65 billion, surpassing the $1.6 billion forecast, while earnings per share reached 78 cents against a predicted 73 cents. CEO Bernard Zovighian highlighted that the quarter built upon solid financial performance and strategic progress achieved throughout 2025.
Following the strong quarterly performance, Edwards raised its full-year sales growth guidance to between 9% and 11%, an increase from its previous outlook of 8% to 10%. The company attributed this upward revision to stronger-than-expected results in the first quarter, signaling continued confidence in its strategic direction and operational execution.
📈 Q1 revenue hit $1.65B, beating expectations of $1.6B.
💰 EPS reached 78 cents, surpassing the 73 cent forecast.
🚀 Shares rose 4.7% after-hours to close at $83.49.
📈 Full-year sales growth guidance raised to 9%-11%.
💬 CEO highlighted solid financial performance and strategic progress.
📈 Edwards Lifesciences reported Q1 revenue of $1.65 billion, beating analyst expectations of $1.6 billion.
💰 Earnings per share reached 78 cents, surpassing the forecasted 73 cents.
🚀 Shares rose 4.7% in after-hours trading to close at $83.49 following the strong results.
📈 The company raised its full-year sales growth guidance to 9%–11%, up from the previous 8%–10%.
💬 CEO Bernard Zovighian highlighted solid financial performance and strategic progress for the quarter.
🏥 As an Irvine-based medical device company, Edwards continues to deliver strong quarterly results in 2025.
Bullish Signals
Shares rose 4.7% after Q1 revenue beat expectations.
Bullish Signals
Edwards Lifesciences Corp. shares rose 4.7% to $83.49 after Q1 revenue of $1.65 billion beat analyst expectations of $1.6 billion.
Earnings per share of 78 cents surpassed the forecast of 73 cents, demonstrating strong profitability.
The company raised its full-year sales growth guidance to 9% to 11%, up from the previous range of 8% to 10%.
The global cardiac care market is experiencing a significant shift driven by heart disease remaining the leading cause of death in the United States despite ongoing medical advancements. Major health authorities, including the World Heart Federation urging the WHO to scale diagnostic infrastructure, are highlighting critical gaps in basic care access, particularly in low and middle-income regions. This structural necessity has attracted substantial investment into the sector, with the global AI cardiology market valued at approximately $2.78 billion in 2026 and projected to reach $14.22 billion by 2034. Key industry players positioning themselves for this opportunity include VentriPoint Diagnostics, Merck, Viatris, United Therapeutics, and Edwards Lifesciences, as diagnostic democratization and targeted therapies emerge as dominant value drivers.
VentriPoint Diagnostics (TSXV: VPT) is central to this innovation wave, expanding into remote healthcare through a partnership with First Light Health to deliver AI-powered diagnostics to Indigenous and remote communities in Canada. The collaboration utilizes the VMS+ system to convert standard 2D echocardiograms into detailed 3D volumetric images comparable to cardiac MRI but at a fraction of the cost without requiring heavy infrastructure. This hub-and-spoke care model enables local providers in provinces such as British Columbia, Yukon, Alberta, Manitoba, and New Brunswick to capture scans while specialists remotely interpret them, significantly reducing travel time and costs for patients in high heart disease rate areas.
Beyond its Canadian expansion, VentriPoint has signed a commercial agreement with LG Consulting Solutions to support VMS+ deployment across Northern California, targeting cardiac centers in the Sacramento and San Francisco regions, following successful pilot work with the Nisga'a Valley Health Authority. The Toronto-based company, which holds regulatory approvals in the US, Canada, and Europe, aims to make MRI-grade diagnostics accessible globally. Concurrently, Merck (NYSE: MRK) is advancing its cardiovascular pipeline with positive Phase 3 results from the CORALreef AddOn trial for enlicitide decanoate, an investigational oral PCSK9 inhibitor that has demonstrated statistically significant LDL-C reductions across three pivotal studies, while also evaluating WINREVAIR in combined post- and precapillary pulmonary hypertension.
💰 AI cardiology market projected to grow from $2.78B to $14.22B by 2034.
🤝 VentriPoint partners with First Light Health to bring affordable AI diagnostics to remote Indigenous communities.
📍 Hub-and-spoke model eliminates travel barriers across five Canadian provinces for advanced cardiac imaging.
💊 Merck reports positive Phase 3 results for its investigational oral PCSK9 inhibitor enlicitide decanoate.
🚀 Major pharma firms position themselves in undervalued spaces tackling the US heart disease epidemic.
🩺 Heart disease remains the top killer in the US despite medical progress, with major gaps in care access prompting global health authorities like the World Heart Federation to call for scaled diagnostic infrastructure.
💰 The global AI cardiology market is valued at $2.78 billion in 2026 and is projected to grow to $14.22 billion by 2034, attracting significant investment capital.
🤝 VentriPoint Diagnostics (TSXV: VPT) has announced a partnership with First Light Health, an Indigenous-owned Vancouver company, to deliver AI-powered cardiac diagnostics to remote and Indigenous communities across Canada.
💻 The collaboration utilizes VentriPoint's VMS+ system to convert standard 2D echocardiograms into detailed 3D volumetric images that are comparable in accuracy to cardiac MRI but at a fraction of the cost.
📍 This hub-and-spoke care model allows patients in British Columbia, Yukon, Alberta, Manitoba, and New Brunswick to access advanced imaging without traveling long distances for specialist interpretation.
🌍 CEO Hugh MacNaught emphasizes that cardiovascular disease does not respect geography, aiming to deploy this solution equitably from the Arctic to the Amazon with potential global scaling beyond Canada.
🤲 First Light Health contributes cultural safety expertise and established relationships within First Nations communities, addressing historical underservement by broader health systems.
📈 VentriPoint previously partnered with the Nisga'a Valley Health Authority for a pilot in northern BC and signed an agreement with LG Consulting Solutions to deploy VMS+ across Northern California.
🔬 The company holds regulatory approvals in the United States, Canada, and Europe, and its platform works with ultrasound equipment from any vendor based on over a decade of technology development.
💊 Merck (NYSE: MRK) presented late-breaking cardio-pulmonary data at ACC.26, showing positive Phase 3 results for enlicitide decanoate, an investigational oral PCSK9 inhibitor that has demonstrated significant LDL-C reductions.
🫁 Merck is also continuing evaluation of WINREVAIR (sotatercept-csrk) in post- and precapillary pulmonary hypertension with heart failure with preserved ejection fraction (CpcPH-HFpEF).
👥 The CORALreef Outcomes cardiovascular outcomes trial for enlicitide has now enrolled over 14,500 participants.
🎯 Dr. Joerg Koglin from Merck stated that the data will underscore the strength of their cardio-pulmonary pipeline aimed at addressing the CV epidemic impacting millions with atherosclerosis and CpcPH-HFpEF.
🚀 United Therapeutics (NASDAQ: UTHR), Viatris (NASDAQ: VTRS), Edwards Lifesciences (NYSE: EW), and Merck are listed among major companies positioned in this undervalued cardiac opportunity space alongside VentriPoint.
Bullish Signals
The global AI cardiology market is projected to grow from $2.78 billion in 2026 to an impressive $14.22 billion by 2034, signaling massive upside potential for innovators.
VentriPoint Diagnostics has secured a partnership with First Light Health to deploy AI-powered cardiac diagnostics across remote and Indigenous communities in Canada, creating a scalable hub-and-spoke care model.
The company's VMS+ system converts standard 2D echocardiograms into MRI-grade 3D volumetric images at a fraction of the cost, offering high accuracy comparable to advanced imaging without expensive infrastructure requirements.
VentriPoint has regulatory approvals in the United States, Canada, and Europe, positioning its technology for global deployment from the Arctic to the Amazon.
Merck (NYSE: MRK) demonstrated strong pipeline momentum with positive Phase 3 results from the CORALreef AddOn trial of enlicitide decanoate, a once-daily oral PCSK9 inhibitor showing statistically significant LDL-C reductions across three pivotal studies.
Merck's investigational therapy is being evaluated in a large outcomes trial with over 14,500 enrolled participants, underscoring the strength and scale of its cardio-pulmonary development program.
Risk Factors
Despite positive industry growth projections ($2.78 billion in 2026 to $14.22 billion by 2034), the global AI cardiology market still faces significant headwinds regarding basic care access gaps in overlooked regions.
Regulatory approvals for VentriPoint Diagnostics are limited to the United States, Canada, and Europe, potentially restricting international expansion beyond stated plans into the Arctic or Amazon.
While First Light Health is Indigenous-owned, deploying health technology in historically underserved populations carries inherent risks of cultural misalignment or community rejection despite stated expertise.
Merck's investigational oral PCSK9 inhibitor enlicitide decanoate remains an investigational product with evaluation still ongoing in the large CORALreef Outcomes cardiovascular outcomes trial involving over 14,500 enrolled participants, creating uncertainty about final approval timing.
VentriPoint's VMS+™ system accuracy is claimed to be comparable to cardiac MRI but lacks independent peer-reviewed validation data for this specific claim in the article text provided.
Edwards Lifesciences Corporation (EW), headquartered in Irvine, California, is a leading global structural heart innovation company with a $48 billion market capitalization. The firm specializes in providing products and technologies for structural heart disease and critical care monitoring, including tissue replacement heart valves, hemodynamic monitoring devices, and pharmaceuticals. Investors are awaiting the company's fiscal first-quarter earnings report for 2026, during which analysts project a diluted profit of $0.72 per share, representing a 12.5% increase from $0.64 per share in the year-ago quarter. Historical performance shows that Edwards has beaten consensus estimates in three of its last four quarters, while missing forecasts on one occasion.
Looking beyond the immediate quarter, financial analysts anticipate EW will report full-year earnings per share (EPS) of $2.96, which would mark a 15.6% increase from $2.56 in fiscal 2025. Long-term projections suggest EPS will rise to $3.30 in fiscal 2027, an 11.5% year-over-year increase. The company has demonstrated significant outperformance relative to broader market benchmarks, gaining 15.5% over the past 52 weeks compared to the S&P 500 Index’s (SPX) 13.4% gains and surpassing returns from the State Street Health Care Select Sector SPDR ETF (XLV). This momentum is largely attributed to strong Transcatheter Aortic Valve Replacement (TAVR) progress and the successful adoption of SAPIEN valve iterations, particularly the new SAPIEN M3 designed for transseptal mitral replacement.
Management's strategic focus on next-generation technologies positions Edwards to meet its $2 billion Total Medical Technologies Target by 2030. The stock carries a "Moderate Buy" rating based on consensus opinion from analysts, with 18 of the 30 coverages recommending a "Strong Buy," two advising a "Moderate Buy," and 10 suggesting a "Hold." The average analyst price target stands at $96.44, implying a potential upside of 17.5% from current levels. These earnings periods are viewed as critical opportunities for gaining deeper management insights that extend beyond standard regulatory approvals, highlighting how established healthcare firms continue to accelerate growth through blockbuster medical device innovations.
*Disclaimer: Neha Panjwani did not have positions in any securities mentioned on the date of publication. All information is for informational purposes and originally published on Barchart.com.*
🏥 Market cap reaches $48B with focus on structural heart technologies.
📈 Q1 2026 profit expected at $0.72, up 12.5% year over year.
🚀 Stock has outperformed the S&P 500 over the last 52 weeks.
🏥 Edwards Lifesciences (EW), based in Irvine, California, holds a $48 billion market cap and specializes in structural heart disease and critical care technologies.
📅 The company is preparing to release its fiscal first-quarter 2026 earnings results in the near term.
💰 Analysts project a Q1 2026 profit of $0.72 per share, representing a 12.5% increase from the previous year.
⚖️ Historically, EW has beaten estimates in three of the last four quarters but missed forecasts on one occasion.
📈 For fiscal 2026, expected annual EPS stands at $2.96, a 15.6% rise from $2.56 in fiscal 2025.
🔮 Long-term growth is anticipated with projected FY2027 EPS reaching $3.30, up 11.5% year over year.
🚀 Stock performance has outpaced the S&P 500's 13.4% gains and XLV ETF returns over the past 52 weeks.
❤️ Revenue momentum is driven by strong TAVR adoption and successful iterations of the SAPIEN heart valve.
💡 Strategic R&D focuses on next-gen technologies like the SAPIEN M3 to help meet a $2 billion sales target by 2030.
👍 Analyst consensus remains moderately bullish, with an average price target of $96.44 indicating 17.5% upside potential.
📊 Of 30 analysts covering the stock, 18 recommend "Strong Buy," while 2 rate it "Moderate Buy" and 10 suggest "Hold."
Bullish Signals
Analysts expect EW to report a profit of $0.72 per share in the upcoming quarter, representing a 12.5% increase from the prior year's $0.64 per share.
For fiscal year 2027, EPS is projected to rise 11.5% year-over-year to $3.30, indicating sustained growth momentum.
EW stock has outperformed both the S&P 500 Index's 13.4% gains and the State Street Health Care Select Sector SPDR ETF over the past 52 weeks.
The company is strategically positioned to meet its $2 billion TMTT sales target by 2030 driven by strong TAVR momentum and successful SAPIEN valve iterations.
Analyst consensus remains moderately bullish, with 18 out of 30 analysts recommending a 'Strong Buy' rating for the stock.
The average analyst price target of $96.44 suggests a potential upside of 17.5% from current trading levels.
Risk Factors
Missing earnings forecasts on one occasion out of the last four quarters, indicating some inconsistency in meeting market expectations.
Out of 30 analysts covering EW stock, 10 advise a 'Hold' rating, showing more than a third are not bullish enough to recommend a strong buy.
The company must meet its $2 billion TMTT sales target by 2030, which represents an ambitious goal with no clear path provided if it falls short.
Analyst consensus is only 'Moderately Bullish' rather than strongly positive, suggesting the stock may face headwinds or competition in the structural heart disease sector.
Royal Philips has received U.S. Food and Drug Administration 510(k) clearance for EchoNavigator R5.0 with DeviceGuide, an artificial intelligence-powered software solution designed to assist physicians during minimally invasive mitral valve repair procedures. Developed in collaboration with Edwards Lifesciences, the technology integrates with the Philips Azurion image-guided therapy platform to combine imaging, real-time data, and intelligent software into a unified workflow. The AI algorithm automatically tracks and visualizes the Edwards PASCAL Ace mitral valve repair device by fusing live echocardiography images from the Philips EPIQ CVxi cardiovascular platform with live X-ray images from the Azurion system. This integration creates a single, integrated view that helps clinicians navigate and position the device with greater clarity and confidence during one of interventional cardiology's most technically demanding procedures.
Mitral regurgitation affects more than 35 million adults worldwide and over 2 million in the United States, prompting the need for alternatives to open heart surgery such as mitral transcatheter edge-to-edge repair (M-TEER). During these complex M-TEER procedures, physicians make a small skin incision to access a vein, allowing catheters to reach the heart where they must position a device delivery system and guide its placement into the diseased mitral valve. The process requires experienced physicians to interpret X-ray and ultrasound images on multiple screens while coordinating movements between operators, making precise adjustments to grasp moving valve leaflets and confirming results in real time. DeviceGuide addresses these challenges by providing an assistive tool that acts as an extra pair of eyes for the medical team without replacing physician expertise.
The software's AI automatically aligns imaging to the device in real time, continuously informing the interventionalist about the location of the device within space on the imaging screen. Dr. Atul Gupta, Chief Medical Officer Diagnosis & Treatment at Philips, emphasized that the technology gives physicians an extra pair of eyes to help them treat more patients safely and confidently, ensuring the physician always remains in control. Leading cardiac professionals involved in the development include Susheel Kumar Kodali, MD, director of the Structural Heart and Valve Center at NewYork-Presbyterian/Columbia University Irving Medical Center, who noted that the visual overlay and trajectory lines simplify the procedure and improve team communication. Additionally, Rebecca T. Hahn, MD, director of interventional echocardiography, stated that the AI minimizes unnecessary repositioning of the imaging window and may improve the precision of device implantation by streamlining procedural guidance.
DeviceGuide will be showcased at the American College of Cardiology (ACC) 2026 meeting in New Orleans as part of Philips' connected cardiology ecosystem aimed at helping physicians care for heart patients from diagnosis through recovery. Mark Stoffels, Business Leader of Image Guided Therapy Systems at Philips, described the technology as a step toward handling the complexity of structural heart procedures among the fastest-growing areas in cardiology. By assisting physicians with real-time visualization and navigation inside the beating heart, the solution aims to help teams manage procedure complexity and perform operations more confidently, ultimately supporting the goal to treat more patients effectively through improved coordination and shared views within the catheterization laboratory workflow.
FDA cleared Philips' new EchoNavigator R5.0 software for mitral valve repair guidance.
DeviceGuide fuses live ultrasound and X-ray views to track devices automatically.
This AI tool simplifies complex M-TEER procedures while preserving physician control.
🚀 FDA grants 510(k) clearance to Philips' new EchoNavigator R5.0 software with DeviceGuide AI solution.
❤️ This technology provides real-time guidance for repairing leaking mitral valves via minimally invasive catheter-based approaches.
🤝 The AI tool was developed in collaboration with Edwards Lifesciences, combining imaging expertise with valvular therapy development.
🌍 Mitral regurgitation affects over 35 million adults globally and more than 2 million in the United States alone.
💡 DeviceGuide fuses live echocardiography images from Philips EPIQ CVxi with X-ray images from the Azurion system into one view.
🧠 The AI algorithm automatically tracks and visualizes the Edwards PASCAL Ace mitral valve repair device during surgery.
👨⚕️ Dr. Atul Gupta states the AI acts as an assistive tool that amplifies physician expertise rather than replacing it.
🏥 Investigators worked closely with sites in Europe and the U.S., including Columbia University Irving Medical Center.
🎯 Dr. Susheel Kumar Kodali notes the software provides visual overlays and trajectory lines to simplify device positioning.
🔍 The system continuously informs interventionalists about the device's location in space relative to the heart valve anatomy.
⚡ This integrated workflow helps physicians manage complexity, improve precision, and treat more patients safely during beating heart procedures.
🔗 DeviceGuide is part of Philips' broader connected cardiology ecosystem supporting patient care from diagnosis through recovery.
📅 The technology will be showcased at the American College of Cardiology (ACC) 2026 meeting in New Orleans.
🧩 M-TEER procedures require experienced teams to coordinate movements and interpret multiple screens for accurate device placement.
🎨 DeviceGuide combines imaging, real-time data, and intelligent software within a unified workflow for more consistent results.
⚠️ The AI minimizes unnecessary repositioning of the imaging window and streamlines procedural guidance for better team coordination.
📈 Structural heart procedures are among the fastest-growing areas in cardiology but also some of the most technically demanding.
🎯 Mark Stoffels highlights that the shared view improves team communication and gives the entire procedure room a clearer picture.
🔒 Physician control remains with the operator, ensuring safety and confidence while navigating complex intracardiac anatomy.
💻 The solution supports Edwards Lifesciences' M-TEER workflow to make these procedures more intuitive and streamlined for clinicians.
🇳🇱 Philips is a global leader in health technology based in Amsterdam with headquarters listed on NYSE and AEX exchanges.
Bullish Signals
Royal Philips announced receipt of U.S. FDA 510(k) clearance for EchoNavigator R5.0 with DeviceGuide, validating its AI-powered solution for assisting physicians during minimally invasive mitral valve repair procedures.
The FDA-cleared software integrates with the Philips Azurion image-guided therapy platform to combine live echocardiography and X-ray images into a single, unified workflow for consistent and efficient procedures.
DeviceGuide was developed in close collaboration with Edwards Lifesciences, aligning both companies' expertise to streamline complex mitral transcatheter edge-to-edge repair (M-TEER) workflows.
The solution helps clinicians navigate and position the Edwards PASCAL Ace mitral valve repair device with greater clarity and confidence during procedures involving over 35 million adults worldwide affected by mitral regurgitation.
By automating tracking and visualization of the repair device, DeviceGuide minimizes unnecessary repositioning of the imaging window and may improve the precision of device implantation.
The AI software serves as an assistive tool rather than a replacement for physician expertise, giving doctors an extra pair of eyes to treat more patients safely and confidently.
DeviceGuide will be showcased at the American College of Cardiology (ACC) 2026 meeting in New Orleans, highlighting its position at a leading forum for cardiovascular innovation.
According to Dr. Susheel Kumar Kodali from NewYork-Presbyterian/Columbia University Irving Medical Center, DeviceGuide simplifies the procedure and improves team communication by providing a single, intuitive presentation of real-time target and orientation.
Mark Stoffels at Philips noted that structural heart procedures are among the fastest-growing areas in cardiology, positioning this innovation to help manage complexity and increase procedural confidence.
Risk Factors
The article contains no negative aspects or risks to summarize as it is an exclusively positive news release about FDA clearance and new product launches, with no mention of declining metrics, regulatory hurdles, financial concerns, or competitive threats.
Zacks Equity Research published an industry outlook on February 24, 2026, highlighting three specific medical instrument companies: Intuitive Surgical (ISRG), Edwards Lifesciences (EW), and Electromed (ELMD). The article argues that these leaders have successfully adapted to changing consumer preferences and macroeconomic headwinds by integrating generative AI (GenAI) into their operations. This integration has moved from experimental phases to operational utility over the last 12 months, enhancing diagnostics, patient monitoring, and workflow efficiency.
The broader context provided includes regulatory shifts, such as the European Commission's December 2025 proposal for simplified medical device rules and new FDA guidance on predetermined change control plans (PCCPs) issued in August 2025 regarding AI-enabled devices. Market data from Fortune Business Insights and Towards Healthcare estimates the global AI in healthcare market at $39.34 billion and $2.65 billion respectively for 2025, with projected Compound Annual Growth Rates of 43.9% and 35.1% through 2034 and 2035.
The article also addresses significant challenges, including high implementation costs, data breach risks, and biased AI outputs derived from incomplete datasets. Macroeconomic pressures like tariffs, staffing shortages, and research funding cuts are noted as obstacles to the MedTech sector. Additionally, a robust merger and acquisition trend is identified, with major deals such as Boston Scientific's $14.5 billion agreement to acquire Penumbra and Danaher's $9.9 billion deal for Masimo Corp driving consolidation in the second half of 2025 and beyond.
Global economic forecasts from the IMF's January 2026 World Economic Outlook predict steady growth at 3.3% for 2026, though concerns remain regarding inflation, fiscal sustainability, and potential disruptions to monetary policy easing. Despite these macro risks, the Zacks Medical Instruments industry maintains a high industry rank due to strong near-term prospects driven by GenAI adoption and consolidation trends.
📅 Zacks Equity Research highlights key medical instrument players with strong near-term prospects.
🤖 Generative AI operationalizes faster, boosting diagnostics and trial recruitment across healthcare sectors.
💰 Global GenAI market reaches $2.65B in 2025, projected to grow at 35.1% CAGR.
⚠ Industry faces high costs, data risks, and regulatory complexities alongside macro headwinds.
🔄 Major M&A activity rebounds with significant deal values exceeding pre-2023 levels.
📅 Zacks Equity Research released an outlook on February 24, 2026, highlighting Intuitive Surgical, Edwards Lifesciences, and Electromed as key players in the medical instruments sector.
🤖 Generative AI (GenAI) has transitioned from experimental to operational use in the last 12 months, improving diagnostics, patient monitoring, and intervention workflows across the industry.
📊 Global AI in healthcare was valued at $39.34 billion in 2025 and is projected to grow at a CAGR of 43.9% through 2034 according to Fortune Business Insights.
⚠️ The industry faces significant challenges including high implementation costs, data breach risks, biased AI outputs, tariffs, staffing shortages, and research funding cuts.
🔄 Regulatory bodies are adapting with the European Commission proposing rule simplifications in December 2025 and the FDA issuing guidance on predetermined change control plans for AI-enabled devices.
🔬 GenAI is reshaping MedTech by speeding up patient recruitment, optimizing trial designs, improving regulatory processes, and enabling hyper-personalized treatment options.
💰 Global GenAI in healthcare was valued at $2.65 billion in 2025 and is expected to expand at a CAGR of 35.1% through 2035 with AI diagnostics growing at 46.1%.
🤝 The medical instrument sector has benefited from a robust merger and acquisition trend, with deal values rebounding above pre-2023 levels in 2025.
📉 Spin-offs and divestitures accounted for more than one-third of strategic deal value in the first 11 months of 2025, up from the previous five-year average.
💼 Major M&A activity included Boston Scientific's $14.5 billion agreement to acquire Penumbra and Danaher's $9.9 billion agreement to acquire Masimo Corp.
🌍 Global economic growth is forecast at 3.3% for 2026 and 3.2% for 2027, marking a slight upward revision for the current year compared to previous estimates.
📉 Global headline inflation is expected to decline from 4.1% in 2025 to 3.8% in 2026, though emerging markets face slower disinflation than advanced economies.
⚠️ The IMF warns that policy-generated disruptions could interrupt the pivot to easing monetary policy, affecting fiscal sustainability and financial stability.
📈 Higher nominal wage growth accompanied by weak productivity may make it difficult for firms to moderate price increases, especially when profit margins are squeezed.
🔝 The Zacks Medical Instruments industry carries an upbeat Industry Rank indicating strong near-term prospects despite broader macroeconomic headwinds.
Bullish Signals
GenAI adoption improved diagnostics and monitoring workflows in 12 months.
Global healthcare AI market hit $39.34B in 2025 with 43.9% CAGR.
Regulators simplified rules via EC proposals and FDA guidance updates.
Hyper-personalization enables predictive treatments through genetic data analysis.
GenAI health market reached $2.65B with 35.1% projected growth.
Diagnostics AI expected to grow at 46.1% through 2034.
M&A deal values rebounded above pre-2023 levels in late 2025.
Boston Scientific acquired Penumbra for $14.5 billion.
Global growth forecast revised upward to steady 3.3% in 2026.
Inflation expected to decline from 4.1% to 3.8% by 2026.
Zacks Medical Instruments holds a strong upbeat near-term outlook.
Risk Factors
Tariffs and staffing shortages weigh heavily on the MedTech sector.
High AI costs and data breach risks obstruct operations.
Steady growth forecasts may limit future expansion potential.
Conflicts and tariffs threaten developing country market growth.
Policy disruptions could raise fiscal sustainability concerns.
Squeezed margins struggle with wage growth outpacing productivity.
Fragmented revenue from frequent spin-offs and divestitures.
New FDA AI rules add regulatory compliance complexity.
Bullish Signals
Generative AI has transitioned from experimental to operational in the last 12 months, improving diagnostics, patient monitoring, and intervention workflows for medical instrument companies.
Global AI in the healthcare market was estimated at $39.34 billion in 2025 and is projected to grow at a CAGR of 43.9% through 2034.
Regulatory bodies are adapting proactively, with the European Commission proposing rule simplifications in December 2025 and the FDA issuing guidance on predetermined change control plans in August.
Hyper-personalization is emerging as a primary feature of GenAI-driven treatment options, enabling predictive treatment and smart hospital systems through vast genetic data analysis.
Global GenAI in the healthcare market is valued at $2.65 billion in 2025 with a projected CAGR of 35.1% through 2035, while AI in diagnostics specifically is expected to grow at 46.1% by 2034.
M&A activity shows robust momentum with deal values rebounding above pre-2023 levels in the second half of 2025 and significant transactions like Boston Scientific's $14.5 billion acquisition of Penumbra.
Global growth is expected to remain steady at 3.3% in 2026, representing a positive upward revision compared to previous forecasts.
Global headline inflation is expected to decline from 4.1% in 2025 to 3.8% in 2026 as advanced economies reach targets sooner.
The Zacks Medical Instruments industry carries an upbeat near-term outlook supported by its strong Zacks Industry Rank.
Risk Factors
Broader macroeconomic pressures, including tariffs and staffing shortages, are weighing on the MedTech sector.
High expenses tied to implementing AI-based solutions, data breach risks, and biased outputs from incomplete or unrepresentative data pose significant operational obstacles for the industry.
Global growth forecasts remain steady at 3.3% in 2026 and 3.2% in 2027, which could limit expansion potential despite AI-driven optimism.
Low-income developing countries face sizable downside growth revisions due to increased conflicts and recent tariff shocks.
Potential policy disruptions to the disinflation process may interrupt the pivot to easing monetary policy, raising concerns about fiscal sustainability.
Higher nominal wage growth accompanied by weak productivity could make it difficult for firms to moderate price increases when profit margins are already squeezed.
Despite positive deal-making trends, spin-offs and divestitures accounted for more than a third of strategic deal value in the first 11 months of 2025, potentially fragmenting revenue streams.
Regulatory bodies are adapting to new AI rules, with the FDA issuing guidance on predetermined change control plans (PCCPs) as part of marketing submissions, introducing potential compliance complexity.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)